Edwards Lifesciences Corp. (NYSE: EW) reported Q2 EPS of $0.88, $0.11 better than the analyst estimate of $0.77. Revenue for the quarter came in at $547 million versus the consensus estimate of $545.1 million.

Edwards Lifesciences Corp. sees FY2014 EPS of $3.24-$3.34, versus prior guidance of $3.10 and the consensus of $3.19. Edwards Lifesciences Corp. sees FY2014 revenue of $2.05-2.25 billion, versus the consensus of $2.17 billion.

"While our litigation settlement provided a large financial gain this quarter, we are particularly pleased that our sales were better than expected across all product lines, which drove strong bottom line results," said Michael A. Mussallem, chairman and CEO. "Even as TAVR competition intensifies, with the increasing adoption of this therapy around the globe, we believe we are poised for continued strong sales growth in the second half of 2014."

For earnings history and earnings-related data on Edwards Lifesciences Corp. (EW) click here.